Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO)
- PMID: 24582783
- DOI: 10.1016/j.bbmt.2014.02.018
Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO)
Abstract
This document updates and expands the recommendations on primary prophylaxis of invasive fungal diseases (IFD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, published in 2009 by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). A consensus process was undertaken to describe and evaluate current information and practice regarding risk stratification and primary antifungal prophylaxis during the pre-engraftment and postengraftment phases after allo-HSCT. The revised recommendations were based on the evaluation of recent literature including a large, prospective, multicenter epidemiological study of allo-HSCT recipients conducted among the GITMO transplantation centers during the period of 2008 to 2010. It is intended as a guide for the identification of types and phases of transplantation at low, standard, and high risk for IFD, according to the underlying disease, transplantation, and post-transplantation factors. The risk stratification was the critical determinant of the primary antifungal approach for allo-HSCT recipients.
Keywords: Allogeneic hematopoietic stem cell transplantation (HSCT); Antifungal prophylaxis; Consensus; Fungal infections.
Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO).Clin Infect Dis. 2009 Oct 15;49(8):1226-36. doi: 10.1086/605665. Clin Infect Dis. 2009. PMID: 19772390
-
Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO).Biol Blood Marrow Transplant. 2014 Jun;20(6):872-80. doi: 10.1016/j.bbmt.2014.03.004. Epub 2014 Mar 14. Biol Blood Marrow Transplant. 2014. PMID: 24631738
-
Comparison of long-term and short-term administration of itraconazole for primary antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: a multicenter, randomized, open-label trial.Transpl Infect Dis. 2014 Apr;16(2):286-94. doi: 10.1111/tid.12192. Epub 2014 Mar 5. Transpl Infect Dis. 2014. PMID: 24593273 Clinical Trial.
-
A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients. Gruppo Italiano Malattie Ematologiche dell'Adulto, Gruppo Italiano Trapianto di Midollo Osseo, Associazione Italiana Ematologia ed Oncologia Pediatrica, Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer and Sorveglianza Epidemiologica delle Infezioni Fungine nelle Emopatie Maligne.Hematol Oncol. 2013 Sep;31(3):117-26. doi: 10.1002/hon.2031. Epub 2012 Oct 5. Hematol Oncol. 2013. PMID: 23037867
-
Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.Pharmacotherapy. 2009 Nov;29(11):1306-25. doi: 10.1592/phco.29.11.1306. Pharmacotherapy. 2009. PMID: 19857148 Review.
Cited by
-
[Chinese expert consensus for invasive fungal disease in patients after hematopoietic stem cell transplantation(2023)].Zhonghua Xue Ye Xue Za Zhi. 2023 Feb 14;44(2):92-97. doi: 10.3760/cma.j.issn.0253-2727.2023.02.002. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 36948861 Free PMC article. Chinese. No abstract available.
-
Saprochaete clavata Invasive Infections - A New Threat to Hematological-Oncological Patients.Front Microbiol. 2019 Oct 29;10:2196. doi: 10.3389/fmicb.2019.02196. eCollection 2019. Front Microbiol. 2019. PMID: 31736883 Free PMC article.
-
Letermovir Primary Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: Real-Life Data from a University Hospital in Argentina.Mediterr J Hematol Infect Dis. 2024 May 1;16(1):e2024039. doi: 10.4084/MJHID.2024.039. eCollection 2024. Mediterr J Hematol Infect Dis. 2024. PMID: 38882462 Free PMC article.
-
Addition of a Single Low Dose of Anti T-Lymphocyte Globulin to Post-Transplant Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplant: A Pilot Study.J Clin Med. 2022 Feb 19;11(4):1106. doi: 10.3390/jcm11041106. J Clin Med. 2022. PMID: 35207379 Free PMC article.
-
Caspofungin for primary antifungal prophylaxis after T-cell-replete haploidentical stem cell transplantation with post-transplant cyclophosphamide.Eur J Haematol. 2019 Apr;102(4):357-367. doi: 10.1111/ejh.13214. Epub 2019 Feb 13. Eur J Haematol. 2019. PMID: 30672611 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical